Abstract
Previously, we described new mechanism of G-CSF-triggered granulocytic differentiation of hematopoietic stem cells (HSCs) via activation of the enzyme Nicotinamide Phosphorybosyltransferase (NAMPT) leading to NAD+ production and activation of NAD+ -dependent protein deacetylase sirtuin 1 (SIRT1). We found, that upon stimulation of HSCs with NAMPT, SIRT1 bound to the key myeloid transcription factor C/EBPα followed by transcriptional induction of C/EBPα target genes G-CSFR and G-CSF and granulocytic differentiation.
In the present work we investigated the mechanism of NAMPT/SIRT1-triggered deacetylation of C/EBPα. We found that C/EBPα is acetylated at the position Lys 161, which is evolutionarily conserved. Lys 161 is localized in the transactivation element III (TE-III) of the transactivation domain (TAD) of C/EBPα protein, which is responsible for recruitment of SWI/SNF and CDK2/CDK4. Western blot and DUOLINK analysis using rabbit polyclonal antibody specifically recognizing acetyl-Lys 161 of C/EBPα revealed predominantly nuclear localization of acetylated C/EBPα protein in acute myeloid leukemia cell lines NB4 and HL60 as well as in primary HSCs. Induction of myeloid differentiation of HSCs by treatment with G-CSF as well as ATRA-induced differentiation of NB4 cells resulted in the deacetylation of C/EBPα. NAMPT inhibition in NB4 and HL60 cell lines using specific inhibitor FK866 led to the dramatically elevated levels of acetylated C/EBPα and reduced amounts of total C/EBPα protein, which was in line with diminished mRNA expression of C/EBPα target genes (G-CSF, G-CSFR and ELANE). Interestingly, treatment of acute myeloid leukemia cell line HL60 with NAMPT or transduction of HL-60 cells with NAMPT-expressing lentiviral construct induced myeloid differentiation of these cells even without addition of ATRA. This was in line with time- and dose-dependent increase of total C/EBPα protein levels upon NAMPT treatment. Therefore, NAMPT overcomes transcriptional repression of C/EBPα in HL-60 cells by activation of positive CEBPA autoregulation.
Taken together, we described a new mechanism of regulation of C/EBPα activities in hematopoiesis and leukemogenesis by its post-translational modification via NAMPT/SIRT1-triggered de-/acetylation.
No relevant conflicts of interest to declare.
Author notes
Asterisk with author names denotes non-ASH members.
![](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/126/23/10.1182_blood.v126.23.2199.2199/3/m_inf01.jpeg?Expires=1742739457&Signature=SBxwrwccnQUR~PmDnSjXlUaKZmtUnESsDrWdnWU4Z6QqNAiHaSDqyhSvtEmYSsFk59X1KGmdL4etdS1XZzeJqJt-v1citfMETSe4dOtyaB8fX6rGtjcXtBiELjadj48nrFirnxGrfRajEW32Kici1yb5Ly5gEy3CI48DEXeBzKPaJQZE3YJ63goMSBRi-1SDUyoN2ON-ItomVBfVVEYD7LaiUBB-lIs6PSJhIkID2VpppJaPEfLtWl98A5he31rRVbHRt0UYWKraM0LgdbYbwZemZ21v92GrhnnFp0u5bWPDJBOi8rIKmVk~~zw32SrKYzia~tkvdEN3MHAmKGyCdg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
This icon denotes a clinically relevant abstract